tiprankstipranks
Biogen (BIIB)
NASDAQ:BIIB

Biogen Stock Forecast & Price Target

3,704 Followers
See the Price Targets and Ratings of:

Analyst Rating Consensus

Moderate Buy
24Ratings
15 Buy
9 Hold
0 Sell
Based on 24 analysts giving stock ratings to
Biogen
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

BIIB Stock Price Prediction

Average Price Target

$258.35
▼(-6.60% Downside)
Based on 24 Wall Street analysts offering 12 month price targets for Biogen in the last 3 months. The average price target is $258.35 with a high forecast of $360.00 and a low forecast of $190.00. The average price target represents a -6.60% change from the last price of $276.61.
Highest Price Target$360.00Average Price Target$258.35Lowest Price Target$190.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Upgrade Banner
Needham
$250.00
Buy
-9.62%
Downside
Reiterated
Biogen (BIIB) Gets a Buy from Needham
Robert W. Baird
$340.00
Buy
22.92%
Upside
Upgraded
Biogen upgraded to Outperform from Neutral at BairdBiogen upgraded to Outperform from Neutral at Baird
Jefferies
$300.00
Buy
8.46%
Upside
Reiterated
Analysts' Top Healthcare Picks: Biogen (BIIB), HCA Healthcare (HCA)
Mizuho Securities
$270.00
Buy
-2.39%
Downside
Upgraded
Biogen Soars 46% on Alzheimers Drug Trial. Mizuho Raises the Stock to Buy.Wall Street also was pleased with the trial results. Mizuho Securities analyst Salim Syed upgraded shares of Biogen to Buy from Neutral and raised his 12-month price target to $270 from $207. He wrote in a research note that there was enough data on the drug from the study that likely allows for regulatory approval and for the debate to largely shift to potential uptake of the product.
Truist Financial
$265.00
Buy
-4.20%
Downside
Reiterated
Biogen price target lowered to $265 from $270 at TruistBiogen price target lowered to $265 from $270 at Truist
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
VTYXVentyx Biosciences
PRVAPrivia Health Group
RXDXPrometheus Biosciences
IMCRImmunocore Holdings
SKINBeauty Health
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

BIIB Stock Forecast FAQ

What is BIIB’s average 12-month price target, according to analysts?
Based on analyst ratings, Biogen’s 12-month average price target is $258.35.
    What is BIIB’s upside potential, based on the analysts’ average price target?
    Currently there's no upside potential for BIIB, based on the analysts’ average price target.
    Can I see which stocks the top-ranking analysts are rating?
    Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
      How can I follow the stock ratings of top Wall Street analysts?
      Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
        Is BIIB a Buy, Sell or Hold?
        Biogen has a conensus rating of Moderate Buy which is based on 15 buy ratings, 9 hold ratings and 0 sell ratings.
          What is Biogen’s price target?
          The average price target for Biogen is $258.35. This is based on 24 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
          The highest analyst price target is $360.00 ,the lowest forecast is $190.00. The average price target represents -6.60% Decrease from the current price of $276.61.
            What do analysts say about Biogen?
            Biogen’s analyst rating consensus is a ‘Moderate Buy. This is based on the ratings of 24 Wall Streets Analysts.

              What's Included in PREMIUM?
              Make informed decisions based on Top Analysts' activity
              Know what industry insiders are buying
              Get actionable alerts from top Wall Street Analysts
              Find out before anyone else which stock is going to shoot up
              Get powerful stock screeners & detailed portfolio analysis